^
    Apply
    This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. (NCT05439499)
    Phase 3
    Ahon Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    07/06/2022
    Initiation :
    03/02/2022
    Primary completion :
    09/20/2024
    Completion :
    03/02/2025
    HER-2 • PGR
    |
    HR positive • HER-2 negative
    |
    letrozole • anastrozole • goserelin acetate • fovinaciclib (FCN-437)
    This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. (NCT05438810)
    Phase 3
    Ahon Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    07/04/2022
    Initiation :
    01/18/2022
    Primary completion :
    02/18/2024
    Completion :
    05/18/2024
    HER-2 • PGR
    |
    HR positive • HER-2 negative
    |
    fulvestrant • goserelin acetate • fovinaciclib (FCN-437)
    Study of FCN-437c in Patients With Advanced Solid Tumors (FCN-437c-001) (NCT03951116)
    Phase 1
    Fochon Pharmaceuticals, Ltd.
    Completed
    Last update posted :
    03/16/2022
    Initiation :
    06/25/2019
    Primary completion :
    12/08/2021
    Completion :
    12/08/2021
    KRAS • ALK
    |
    KRAS mutation • ALK translocation
    |
    fovinaciclib (FCN-437)
    Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin (NCT05004142)
    Phase 2
    Ahon Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    08/13/2021
    Initiation :
    06/30/2020
    Primary completion :
    12/30/2021
    Completion :
    06/30/2023
    HER-2 • ER
    |
    HER-2 negative
    |
    fulvestrant • letrozole • goserelin acetate • fovinaciclib (FCN-437)
    Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c (NCT04488107)
    Phase 1/2
    Ahon Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    07/27/2020
    Initiation :
    02/14/2019
    Primary completion :
    12/31/2021
    Completion :
    06/30/2022
    HER-2
    |
    letrozole • fovinaciclib (FCN-437)